Received Jun 10, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Redness; Itching; possible cellulitis; This non-serious case was reported by a other health professional and described the occurrence of erythema in a 53-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included rosuvastatin and montelukast. On 21-MAY-2026, the patient received Shingrix. In MAY-2026, less than a week after receiving Shingrix, the patient experienced cellulitis (Verbatim: possible cellulitis). On 22-MAY-2026, the patient experienced erythema (Verbatim: Redness) and pruritus (Verbatim: Itching). On 27-MAY-2026, the outcome of the erythema and pruritus were resolving (duration 5 days). The outcome of the cellulitis was not reported. It was unknown if the reporter considered the erythema, pruritus and cellulitis to be related to Shingrix. Additional Information: GSK Receipt Date: 30-MAY-2026 The patient was treated for possible cellulitis at emergency room and saw the internist 3 days later, it was still red but less so, the internist felt it was a local reaction and not infection. The batch number was not provided upon follow- up with the reporter.
ROSUVASTATIN; MONTELUKAST